Merck & Company Inc (MRK) Peer Comparison
$150.44
$-1.90
(-1.25%)
As on 04-Sep-2026 13:43EDT
Market cap
$367,584 Mln
Revenue (TTM)
$66,400 Mln
P/E Ratio
122.1
P/B Ratio
9
Div. Yield
2.2 %
Edit
| Merck & Company Inc (MRK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Novartis AG - ADR | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
367,584 | 1,109,683 | 644,335 | 462,684 | 296,968 |
Revenue ($ Mln) |
66,400 | 79,666 | 97,929 | 64,386 | 55,635 |
Net Profit ($ Mln) |
3,173.00 | 26,709.50 | 21,037.00 | 6,314.00 | 12,759.05 |
Net Margin (%) |
4.78 | 33.53 | 21.48 | 9.81 | 22.93 |
RoE (%) |
6.72 | 88.42 | 25.27 | -- | 29.13 |
Price to Earnings |
122.12 | 42.93 | 31.75 | 75.24 | 23.60 |
Price-To-Book |
8.95 | 33.69 | 7.75 | 50.46 | 7.33 |
Income Statement ($ Mln)
| Merck & Company Inc (MRK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Operating Revenue
|
66,400.00 | 79,665.80 | 97,929.00 | 64,386.00 | 55,634.86 |
|
Cost of Revenue
|
16,350.00 | 12,737.00 | 28,936.00 | 18,365.00 | 14,220.25 |
|
Gross Profit
|
46,731.00 | 54,615.00 | 68,558.00 | 42,956.00 | 41,121.51 |
|
Operating Expenses
|
38,994.00 | 31,939.40 | 42,737.00 | 27,142.00 | 24,422.63 |
|
Operating Profit (EBIT)
|
11,056.00 | 34,989.40 | 26,256.00 | 18,879.00 | 16,991.98 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
5,948.00 | 33,594.40 | 25,196.00 | 8,699.00 | 15,524.68 |
|
Provision for Tax
|
2,779.00 | 6,884.90 | 4,159.00 | 2,383.00 | 2,775.63 |
|
Profit after Tax (Net Income)
|
3,173.00 | 26,709.50 | 21,037.00 | 6,314.00 | 12,759.05 |
|
Minority Interest
|
4.00 | 0.00 | 0.00 | -6.00 | 10.00 |
|
Consolidated Profit
|
8,748.00 | 12,218.50 | 10,268.00 | 0.00 | 6,337.00 |
Liabilities ($ Mln)
| Merck & Company Inc (MRK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
41,933.00 | 33,879.00 | 84,971.00 | -5,935.00 | 41,542.17 |
|
Minority Interest
|
4.00 | 0.00 | 0.00 | -6.00 | 10.00 |
|
Non-Current Liabilities
|
60,087.00 | 60,663.00 | 61,195.00 | 99,361.00 | 48,339.19 |
|
Current Liabilities
|
27,731.00 | 47,741.00 | 54,895.00 | 41,642.00 | 31,748.13 |
|
Total Liabilities
|
136,866.00 | 112,476.00 | 199,210.00 | 133,960.00 | 115,569.20 |
Assets ($ Mln)
| Merck & Company Inc (MRK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
93,123.00 | 77,611.00 | 141,286.00 | 101,446.00 | 94,682.38 |
|
Current Assets
|
36,679.00 | 64,672.00 | 59,774.00 | 33,669.00 | 27,351.11 |
|
Total Assets
|
136,866.00 | 112,476.00 | 199,210.00 | 133,960.00 | 115,569.20 |
|
Total Debt*
|
53,906.00 | 54,908.00 | 49,036.00 | 70,822.00 | 49,014.20 |
|
Net Current Assets
|
8,948.00 | 16,931.00 | 4,879.00 | -7,973.00 | -4,397.00 |
Cashflow ($ Mln)
| Merck & Company Inc (MRK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
16,472.00 | 16,813.00 | 24,530.00 | 19,030.00 | 19,242.03 |
|
Cash Flow from Investing Activities
|
-13,741.00 | -10,972.00 | -23,588.00 | -6,643.00 | -4,901.98 |
|
Cash from Financing Activities
|
-1,922.00 | -2,213.00 | -5,539.00 | -12,724.00 | -14,943.13 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Merck & Company Inc (MRK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
ROCE (%)
|
19.45 | 35.32 | 22.56 | 6.17 | 17.74 |
|
ROE (%)
|
6.72 | 88.42 | 25.27 | 6,214.71 | 29.13 |
|
ROA (%)
|
2.11 | 16.19 | 8.36 | 3.57 | 8.80 |
|
EBIT Margin (%)
|
10.86 | 31.17 | 26.53 | 20.68 | 30.41 |
|
Net Margin (%)
|
4.78 | 33.53 | 21.48 | 9.81 | 22.93 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Merck & Company Inc (MRK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
4.24 | 49.58 | 8.06 | 10.39 | 0.81 |
|
EBIT Growth (%)
|
-64.72 | 39.73 | -7.83 | 125.97 | 1.26 |
|
Net Profit Growth (%)
|
-80.66 | 93.55 | -7.17 | 67.79 | -6.55 |
|
EPS Growth (%)
|
-80.70 | 94.62 | -7.72 | 67.77 | -3.44 |
|
Book Value Growth (%)
|
-12.99 | 86.67 | 7.35 | -4,203.16 | 1.32 |
Valuation Ratios
| Merck & Company Inc (MRK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Price / Earnings
|
14.35 | 46.76 | 18.83 | 95.92 | 18.92 |
|
Price / Book Value
|
4.98 | 36.37 | 6.19 | -125.57 | 5.77 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
10.54 | 35.81 | 12.97 | 26.61 | 12.68 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Merck & Company Inc (MRK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Debt to Equity
|
1.22 | 1.41 | 0.44 | -10.53 | 0.90 |
|
Short term debt to equity ratio
|
0.07 | 0.21 | 0.14 | -1.41 | 0.24 |
|
Current Ratio
|
1.32 | 1.35 | 1.09 | 0.81 | 0.86 |
|
Quick Ratio
|
1.10 | 1.00 | 0.81 | 0.69 | 0.67 |
|
Interest Coverage
|
4.41 | 35.29 | 25.90 | 3.98 | 12.17 |
Operating Efficiency Ratios
| Merck & Company Inc (MRK) | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | AbbVie (ABBV) | Novartis AG - ADR | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
18.92 | 29.47 | 19.45 | 21.47 | 17.71 |
|
Asset Turnover
|
0.44 | 0.48 | 0.39 | 0.36 | 0.38 |
|
Receivable days
|
64.57 | 93.67 | 70.00 | 70.20 | 63.79 |
|
Inventory Days
|
128.14 | 368.80 | 189.75 | 91.61 | 159.98 |
|
Payable days
|
85.14 | 148.80 | 158.88 | 65.58 | 120.44 |
|
Cash Conversion Cycle
|
107.57 | 313.66 | 100.87 | 96.23 | 103.33 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
